ESTRO 2024 - Abstract Book

S2461

Clinical - Urology

ESTRO 2024

maximal adherence). As secondary outcomes, the change from baseline in fasting serum metabolic and inflammatory biomarkers will be monitored. Intestinal microbiome composition will be evaluated trough fecal samples analyses. According to the cross-over design, the CG will cross to the IG after 6 months, to actively enhance compliance towards suggested lifestyle recommendations for all pts.

Results:

Recruitment started on October 2021 and to date, 287 pts have been enrolled (139 allocated to IG and 148 to CG) with a median age at recruitment of 71 years. Baseline characteristics of pts are reported in Figure 1. A totale of 485 fecal samples were collected at different timepoint. One-hundred and ninety pts completed the RT course with no grade (G) ≥3 gastrointestinal (GI) acute toxicities reported and only 2 genitourinary (GU) G≥3 acute toxicities observed among both arms. The HLA score resulted significantly higher at 6 months (data available for 47 pts) with respect to baseline (median HLA 4.4 vs 4.8, p < .0001, Figure 2a). When stratifying pts according to BMI at baseline, pts with a BMI ≥ 30 had a greater increase in HLA at 6 months. While, when stratified by age, pts aged 66 -75 resulted the ones with a major change in HLA score (Figure 2b). At 12-month FU (data available for 27 pts) all pts are alive with no evidence of disease and only one GI ≥G3 late toxicity was reported.